Immuno-Oncology | Specialty

PD-1 Inhibitors in Hodgkin Lymphoma

July 20th 2016

Immunotherapy Response Among Hematologic Malignancies

July 20th 2016

Immunotherapy: What is the Role in Lymphoid Cancers?

July 20th 2016

Dr. Wakelee on Immunotherapy Versus Targeted Agents in NSCLC

July 20th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

Pancreatic Cancer: Where to Next?

July 20th 2016

The Future of Pancreatic Cancer

July 20th 2016

Immunotherapy in Pancreatic Cancer

July 20th 2016

Novel Agents in Pancreatic Cancer

July 20th 2016

PARP Inhibitors in Pancreatic Cancer

July 20th 2016

Third-Line Therapy for Pancreatic Cancer

July 20th 2016

Pancreatic Cancer: Updated NCCN Guidelines

July 20th 2016

The NAPOLI-1 Trial in Pancreatic Cancer

July 20th 2016

Pancreatic Cancer Therapeutic Sequencing

July 20th 2016

Therapy for Locally Advanced Pancreatic Cancer

July 20th 2016

Adjuvant Therapy in Locally Advanced Pancreatic Cancer

July 20th 2016

Practical Considerations in Chemotherapy Regimens for Pancreatic Cancer

July 20th 2016

Pancreatic Cancer Upfront Therapy

July 20th 2016

Continued Challenges in Pancreatic Cancer Research

July 20th 2016

Kris Looks Ahead to Lung Cancer Care With Immunotherapy in Spotlight

July 20th 2016

Mark W. Kris, MD, discusses immunotherapy, frontline therapies for nonsquamous non–small cell lung cancer, and advancements in squamous cell carcinoma.

Immunotherapy/Chemo Combinations Show Potential in NSCLC

July 19th 2016

Shirish Gadgeel, MD, discusses the KEYNOTE-021 and KEYNOTE-189 studies, which are both examining pembrolizumab with chemotherapy in patients with non–small cell lung cancer.